Crucell and DSM Biologics Announce PER.C6 Licensing Agreement with UMN Pharma
Crucell N.V. and allied contract manufacturer DSM Biologics announced that they have signed a PER.C6® research license agreement with Japanese pharmaceutical company UMN Pharma. This license agreement allows UMN Pharma to use the PER.C6® cell line in its 'UMN-03' project, which aims to employ a fusion protein in the treatment of muscular dystrophy and metabolic diseases such as obesity and type II diabetes mellitus.
In addition, Crucell and DSM Biologics will provide UMN Pharma with various services including vector construction, clone generation, process development and cGMP manufacturing, through its own facilities in Groningen, The Netherlands and within the PER.C6® vendor network.
Under the terms of the agreement, UMN Pharma will pay a signing fee and annual maintenance fees. The additional services will also attract fees. Further financial details are not disclosed.
Topics
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.